ABOLOGIX signs a license agreement with Research Development Foundation for two monoclonal antibodies for oncology
- branding425
- Jul 20, 2018
- 1 min read
Geneva, Switzerland, July 19, 2018 – Abologix has entered into an exclusive, worldwide in-license agreement with Research Development Foundation for two monoclonal antibodies for oncological indications that were developed at the University of Geneva with funding from Institut Clayton de la Recherche.
コメント